Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement
Mandate

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

July 19, 2024 M&A

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.

Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a EUR 600 million financing agreement with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.

The new facility of EUR 600 million is used to refinance Embracer’s existing revolving credit facilities of SEK 4.8 billion. The terms and conditions for the new facility have been improved, including a notably lower credit margin for utilised debt, which will reduce interest expenses through both improved terms and a reduced financial leverage.

Vinge’s team consisted of Albert Wållgren, Felix Möller, Ida Redander and Josef Groow.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026